delpazolid

Delpazolid is a next-generation oxazolidinone antibiotic under clinical development for the treatment of tuberculosis and other mycobacterial infections. It acts as a protein synthesis inhibitor by targeting the bacterial ribosome (23S rRNA), similar to linezolid but with an improved safety profile. Delpazolid demonstrates activity against multidrug-resistant Mycobacterium tuberculosis and various Gram-positive pathogens including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci. Developed originally by LegoChem Biosciences (now LigaChem Biosciences), it is being evaluated in Phase II trials for pulmonary tuberculosis and nontuberculous mycobacterial infections[2][3][6][7].

Brand names

delpazolid

Other names

(5R)-3-(3-fluoro-4-(1-methyl-5,6-dihydro-1,2,4-triazin-4-yl)phenyl)-5-(hydroxymethyl)oxazolidin-2-one(R)-3-[3-Fluoro-4-(1-methyl, 1,4,5,6-tetrahydro 1,2,4-triazin 4 yl)phenyl]-5(R)-(hydroxymethyl)oxazolidin 2 one